VRX Latest News, Press Relases and Analysis

All

Press Releases

7 years ago - By: Barron's - Mentions: XPH XLV

Valeant: It’s More Than Just Dermatology

6 years ago - By: InvestorPlace - Mentions: TEVA CHK GWPH CSIQ ...

9 High-Risk Stocks to Buy for Massive Rewards

6 years ago - By: Bausch Health Companies Inc. - Mentions: BHC

Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6

7 years ago - By: InvestorPlace - Mentions: TEVA CHK GWPH CSIQ ...

9 High-Risk Stocks to Buy for Massive Rewards

7 years ago - By: Benzinga - Mentions: XBI BIIB CELG IBB ...

6 Valuable Pipeline Drugs With Upcoming Catalysts

7 years ago - By: Analyst Ratings

H.C. Wainwright Upgrades Valeant Pharm International (VRX) to Buy

7 years ago - By: Bausch Health Companies Inc. - Mentions: BHC

Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses

7 years ago - By: InvestorPlace - Mentions: TEVA CHK GWPH CSIQ ...

9 High-Risk Stocks to Buy for Massive Rewards

7 years ago - By: Analyst Ratings

Valeant Pharm International (VRX) Gets a Buy Rating from Cantor Fitzgerald

7 years ago - By: Bausch Health Companies Inc. - Mentions: BHC

Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States

7 years ago - By: Bausch Health Companies Inc. - Mentions: BHC

Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology

7 years ago - By: InvestorPlace - Mentions: PYX CGC STZ NBEV ...

Pyxus Stock Could Backfire Over the Longer Term

7 years ago - By: InvestorPlace - Mentions: CRON STZ CGC TLRY ...

There’s Just No Reason to Rush Into Cronos Stock

7 years ago - By: InvestorPlace - Mentions: TEVA CHK GWPH CSIQ ...

9 High-Risk Stocks to Buy for Massive Rewards

7 years ago - By: The Motley Fool - Mentions: BHC

Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018

7 years ago - By: MarketNewsUpdates.com - Mentions: STAA EYEG AGN

International Ophthalmology and Optometry Devices Market Booming With New Growth Opportunities

7 years ago - By: Benzinga - Mentions: ALNY DRRX FOLD IBB ...

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

7 years ago - By: Smarter Analyst

Mizuho Sets Expectations on Valeant (VRX) Ahead of Earnings

7 years ago - By: InvestorPlace - Mentions: CELG GILD PFE BIIB ...

3 Real Risks That Could Make You Reconsider Buying Celgene Stock

7 years ago - By: TalkMarkets - Mentions: OIL NDX SPX NYA ...

2,800 Tuesday and the S&P – Are We There Yet?

7 years ago - By: Bausch + Lomb

Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%

7 years ago - By: InvestorPlace - Mentions: TEVA AGN SNY PFE ...

5 Pharmaceutical and Biotech Stocks to Consider for July

7 years ago - By: MarketWatch - Mentions: SPX DJIA

Valeant is back on to its old drug-pricing ways

7 years ago - By: TalkMarkets - Mentions: SYN

VALEANT PHARMACEUTICALS INTL I (VRX) Stock News

VRX Latest News, Press Relases and Analysis

Valeant: It’s More Than Just Dermatology

9 High-Risk Stocks to Buy for Massive Rewards

Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6

9 High-Risk Stocks to Buy for Massive Rewards

6 Valuable Pipeline Drugs With Upcoming Catalysts

H.C. Wainwright Upgrades Valeant Pharm International (VRX) to Buy

Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses

9 High-Risk Stocks to Buy for Massive Rewards

Valeant Pharm International (VRX) Gets a Buy Rating from Cantor Fitzgerald

Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States

Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology

Pyxus Stock Could Backfire Over the Longer Term

There’s Just No Reason to Rush Into Cronos Stock

9 High-Risk Stocks to Buy for Massive Rewards

Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018

International Ophthalmology and Optometry Devices Market Booming With New Growth Opportunities

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Mizuho Sets Expectations on Valeant (VRX) Ahead of Earnings

3 Real Risks That Could Make You Reconsider Buying Celgene Stock

2,800 Tuesday and the S&P – Are We There Yet?

Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%

5 Pharmaceutical and Biotech Stocks to Consider for July

Valeant is back on to its old drug-pricing ways

Mizuho Says Synthetic Biologics IBS Treatment May Be 'Interesting' For Valeant